6114E89B-B007-4F1B-B086-21ADE26F4573
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 39.12614980289093
- age_years
- 25
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.511
- TGF_BETA_SIGNALING+0.465
- NOTCH_SIGNALING+0.423
- WNT_BETA_CATENIN_SIGNALING+0.411
- MYC_TARGETS_V2+0.359
- MITOTIC_SPINDLE+0.345
- HEDGEHOG_SIGNALING+0.330
- DNA_REPAIR+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.286
- TNFA_SIGNALING_VIA_NFKB+0.275
Top 10 suppressed
- KRAS_SIGNALING_DN-0.397
- SPERMATOGENESIS-0.305
- ALLOGRAFT_REJECTION-0.186
- PANCREAS_BETA_CELLS-0.115
- ANGIOGENESIS-0.104
- COAGULATION-0.101
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.092
- MYOGENESIS-0.074
- GLYCOLYSIS-0.022
- COMPLEMENT-0.021
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C6ACBA34-164B-419D-9C2B-ED2DC3C68FDD | — | — | 0.910 |
| 2 | 8441B707-EC45-4A38-8B83-99B8D83CCF8B | — | — | 0.907 |
| 3 | 67B5E93E-6F06-4247-86DD-A914279EFFC5 | — | — | 0.903 |
| 4 | SRR934756 | — | — | 0.880 |
| 5 | 7E9D6B6D-3276-4240-B5C5-F3F982076358 | — | — | 0.867 |
| 6 | 7CE18C10-61E6-45FA-B9AF-408CD673C0C9 | — | — | 0.859 |
| 7 | 53BA607F-7939-40D9-BEFA-DC4ABDC7630B | — | — | 0.859 |
| 8 | AE32CA37-A422-42E3-AA29-0149CF1A3019 | — | — | 0.859 |
| 9 | SRR934764 | — | — | 0.854 |
| 10 | 53426017-24F2-4348-BEE1-05E80B6A0E6B | — | — | 0.843 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.511 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.465 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.423 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.411 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.359 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.345 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.286 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.275 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.274 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.261 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.219 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.195 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.191 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.188 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.185 | Inavolisib | — uncovered |
| APOPTOSIS | 0.182 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.155 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.152 | Inavolisib | — uncovered |